PureTech grabs up to $36M from Roche to research milk-inspired delivery platform
The quiet R&D work that PureTech Health has been putting into its lymphatics and immune cell trafficking programs is paying off with an announcement this morning that Roche is handing up to $36 million to see if PureTech’s Mammalian-derived exosome platform tech can create oral formulations of Roche’s antisense therapies.
That potential figure covers upfront payments, research support and early preclinical milestones. And beyond that, Roche has also promised more than $1 billion in store for PureTech if it reaches certain development and sales milestones. There’s no word on how many programs they are expecting to pursue under the agreement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.